+

WO2012013587A1 - Ensemble aiguille multiple pour un dispositif d'injection - Google Patents

Ensemble aiguille multiple pour un dispositif d'injection Download PDF

Info

Publication number
WO2012013587A1
WO2012013587A1 PCT/EP2011/062606 EP2011062606W WO2012013587A1 WO 2012013587 A1 WO2012013587 A1 WO 2012013587A1 EP 2011062606 W EP2011062606 W EP 2011062606W WO 2012013587 A1 WO2012013587 A1 WO 2012013587A1
Authority
WO
WIPO (PCT)
Prior art keywords
cannulae
medicament
needle assembly
needle
cannula
Prior art date
Application number
PCT/EP2011/062606
Other languages
English (en)
Inventor
Christopher James Smith
Alastair Robert Clarke
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of WO2012013587A1 publication Critical patent/WO2012013587A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3295—Multiple needle devices, e.g. a plurality of needles arranged coaxially or in parallel
    • A61M5/3298—Needles arranged in parallel

Definitions

  • the present disclosure relates to needle assemblies for injection devices, more particularly to needle assemblies that have two or more needle cannulae separately mounted in a hub that attaches to an injection device. This disclosure also relates to an injection device.
  • the art has recognized a need to inject two or more medications or medicaments simultaneously and has disclosed injection devices that hold two cartridges of medication. For example, it is medically desirable in the treatment of certain conditions of the human body to administer several types and dosage amounts of medication simultaneously.
  • the treatment of diabetes is one such example.
  • Different types of insulin act in different fashions. A fast acting insulin works quickly but for a short period of time after administration, whereas a longer acting insulin takes effect more slowly, but for a longer period of time. Attempts to simultaneously inject both regular, fast acting insulin and long lasting insulin when needed have met with limited success, especially when the medication is forced to flow from the two cartridges through a manifold and out a single cannula in fluid communication with the manifold.
  • Blockage of the manifold and high injection force are two of the problems encountered by such previously proposed devices. Accordingly, there exists a need to provide users of such injection devices with an easy to use device that allows for the simultaneous injection of two or more medicaments or that provide a low injection force. It is an object of the present disclosure to facilitate provision of a novel, preferably an improved, injection device.
  • This disclosure may provide an improved needle assembly, and preferably an improved injection device, where two or more needle cannulae are mounted separately in a hub that is attached to or is configured to be attached to the injection device.
  • the needle assembly comprises a hub.
  • the hub may have a central axis.
  • the hub may have a non-threaded connector, which may be configured to attach to an injection device, particularly to a distal end of the injection device.
  • the needle assembly further comprises at least two cannulae. Each cannula has a distal end and a proximal end. Each cannula is mounted separately in the hub. The distal end and/or the proximal end of each cannula may be beveled and/or sharp.
  • a needle assembly configured for attaching to an injection device, preferably without using a threaded connection.
  • the needle assembly has a hub portion with a central axis and a non-threaded connector, such as snap lock, which may be configured such that the hub can be pushed (as opposed to rotated) onto the distal end of an injection device.
  • the hub contains at least two needle cannulae, each having distal and proximal ends and mounted separately in the hub off center of the central axis. The distal and/or proximal ends of each cannula may be beveled and/or sharp, particularly sharpened.
  • the needle assembly is preferably designed for a single use and easily disposable.
  • each cannula do not extend beyond the needle assembly or the hub portion.
  • bevels on the distal ends of the cannulae are facing outwards from the central axis of the hub. In another embodiment the bevels on the distal ends of the cannulae are facing towards the central axis of the hub.
  • the bevels on the distal ends of the cannulae are facing in the same direction.
  • the surface normals of two bevels when viewed in projection from the distal side or in top view onto the distal ends of the cannulae, may be oriented collinearly.
  • the bevel on the distal end of a first cannula may face a second cannula with the bevel on the distal end of the second cannula facing away from the bevel of the first cannula.
  • the bevels on the distal ends of two cannulae are facing each other.
  • the bevels on the distal ends of the cannulae are facing in different, preferably opposite, directions.
  • the bevel on the distal end of one of the at least two cannulae may face away from the bevel on the distal end of another one of the at least two cannulae.
  • the different orientations of the bevels on the distal ends with respect to the central axis or with respect to each other as described above provide the possibility to adjust the needle assembly to suit different requirements.
  • Such requirements may include the way how the medicament spreads within the tissue, how much medicament may reach a predefined region within the tissue, preventing mixing of two medicaments within the tissue, particularly near the injection site, etc.
  • the bevel of the cannula may be arranged to face away from this region. If, to the contrary, it is desired to direct medicament to this region, the bevel is expediently arranged to face this region.
  • the respective medicament can be directed to desired regions within the tissue or the spreading of medicament may be made more uniform by adjusting the orientation of the bevels with respect to each other or with respect to the central axis.
  • mixing of medicaments originating from different cannulae may be promoted or prevented, depending on how the bevels are oriented with respect to each other. If two bevels face each other, mixing may be promoted. If two bevels face away from each other, mixing may be prevented. If two bevels face in the same direction the spreading of medicament in a direction opposite to the one defined by the bevels may be prevented.
  • each needle cannula is of a different gauge and/or length compared to the other cannula.
  • the exact size and geometry of each cannula may be selected to suit the properties and delivery requirements of the medicament within the cartridge or reservoir associated with that particular cannula.
  • the distal ends of the cannula can be separated by a distance equal to, less than or greater than D.
  • the distance selected may depend on the corresponding injection device and may require the necessity to only permit the needle assembly to be attached to the injection device in one particular orientation, for example, so that each cartridge is pierced by the correct geometry needle. Such a special orientation also ensures that if the needle attachment is removed and reattached for any reason then any residual medicament on the septum piercing ends of the needles does not contaminate another cartridge.
  • Injection of a double needle may be a cause of anxiety or inconvenience to a user.
  • a user will normally inject sub-cutaneous injections into a fold of skin. This may be more difficult with a double needle, particularly if the distance between the needles or needle cannulae is large as the skin fold will need to be larger to
  • the two or more needles or needle cannulae are brought closer together.
  • the distance of the distal ends of the cannula is much less than D, the distance between the proximal ends of the cannulae.
  • the distance between the distal ends may be less than 0.5 D, preferably 0.3 D or less, particularly preferably 0.2 D or less, such as 0.1 D or less.
  • At least one cannula preferably more than one cannula, is non- linear with respect to the central axis such that the proximal end is offset from the distal end.
  • the two or more needle cannulae mounted in the hub are not necessarily straight and parallel, however, it is preferred that the injected portion or distal portion of the cannula (the sharp or sharpened distal end) and the septum piercing portion or proximal portion (the sharp or sharpened proximal end) of the needle or needle cannula should be straight.
  • the injected portions or distal portions of each needle should be parallel to each other and, preferably, perpendicular to the injection site.
  • the septum piercing portions or proximal portions of each needle or needle cannula should be parallel to each other and, preferably, parallel to the proximal portions. This may permit axial attachment of the multiple needle assembly.
  • the septum piercing portions or proximal portions may be perpendicular to the cartridge or reservoir septum.
  • the portion of the needle or needle cannula in between the injected portion or distal portion and the septum piercing portion or proximal portion may be bent, curved or angled. Such a configuration will allow for varying the distances between the cannulae.
  • One, two or more straight portions of the respective cannula are preferably collinear.
  • One, two or more straight portions of the respective cannula may be oriented axially, e.g. along the central axis of the hub.
  • an aspect of this disclosure relates to an injection device or an injection assembly comprising medicament.
  • the device or assembly further comprises a needle assembly, preferably a needle assembly as described above.
  • the at least two cannulae of the needle assembly are in fluid communication with medicament.
  • the medicament may be arranged within a medicament housing.
  • the medicament housing may have a non- threaded connector.
  • the non-threaded connector of the needle assembly may cooperate with the non-threaded connector of the medicament housing to connect the needle assembly to the housing.
  • each cannula do not extend beyond the needle assembly or the hub portion.
  • the proximal ends of each cannula are covered by the hub portion of the needle assembly. This feature improves safe handling of the needle assembly and protects from needle stick injury when attaching the needle assembly to an injection device.
  • the needle assembly and the injection device are adapted such that the needle assembly may be attached to the injection device only in a single orientation with respect to the injection device. Bringing a wrong cannula in fluid communication with a medicament may be prevented in this way.
  • one of the at least two cannulae is in fluid communication with medicament of a first reservoir or cartridge of medicament and another one of the at least two cannulae is in fluid communication with medicament of a second reservoir or cartridge of medicament.
  • two cannulae are in fluid communication with medicament of a single reservoir or cartridge of medicament.
  • This disclosure particularly also covers an injection device having a needle assembly, preferably the needle assembly as described above.
  • the needle assembly may be removably or permanently attached to a medicament housing.
  • the medicament housing may contain or comprise one or more cartridges or reservoirs of medicament, with each preferably having a pierceable membrane or septum in fluid communication with a medicament.
  • the injection device may also have a dose setting module attached to the medicament housing.
  • the dose setting module may contain known dose setting and injection mechanisms that may interact with the reservoirs or cartridges of medicament to cause the medicament to flow through the needle cannula during injection.
  • the proximal ends of the needle cannulae are preferably sufficiently sharp to allow penetration of the membrane or septum so that the needle cannula is in fluid
  • the needle assembly may be removably or permanently attached to a medicament housing and the needle assembly comprises two needle cannulae.
  • the medicament housing may contain or comprise two cartridges or reservoirs of medicament, with each preferably having a pierceable membrane or septum in fluid communication with a medicament.
  • the injection device may also have a dose setting module attached to the medicament housing.
  • the dose setting module may contain known dose setting and injection mechanisms that may interact with the reservoirs or cartridges of medicament to cause the medicament to flow through the needle cannulae during injection.
  • the proximal ends of the needle cannulae may be configured to pierce a septum or seal or membrane.
  • the proximal ends of the needle cannulae are preferably sufficiently sharp to allow penetration of the membrane or septum so that each needle cannula is in fluid communication with the medicament.
  • the first needle cannula can pierce the septum of the first reservoir and will establish fluid communication to a first medicament and the second needle cannula can pierce a septum of the second reservoir and will establish fluid communication to a second medicament in use.
  • the multiple needle assembly is specifically configured for attachment to an injection device having a single reservoir or cartridge of medicament.
  • This configuration provides two main advantages, reduced injection pain and reduced injection force (or conversely reduced injection time for a given force).
  • two or more needles are arranged within the needle assembly in such a manner as to permit all of the needles to pierce a single septum.
  • the needles are not connected and are arranged, possibly using curved or angled needles as described above and illustrated in the accompanying figures.
  • a needle assembly for an injection device comprising,
  • a hub having a central axis and a non-threaded connector configured to attach to a distal end of an injection device
  • each cannula mounted separately in the hub, where the distal and proximal ends of each cannula are beveled and sharp.
  • the needle assembly of aspect 1 having two cannula where the proximal ends are separated by a distance D and the distance separating the distal ends is less than D.
  • the needle assembly of aspect 1 having two cannula where the proximal ends are separated by a distance D and the distance separating the distal ends is greater than D.
  • the needle assembly of aspect 1 where at least one cannula is non-linear with respect to the central axis such that the proximal end is offset from the distal end.
  • An injection device comprising the following in combination,
  • a first and a second reservoir of medicament located inside the housing, each having a septum in fluid communication with the medicament in the respective reservoir;
  • a needle assembly non-threadedly attached to the connector having a hub with a central axis and having mounted therein at least two needle cannulae having distal and proximal ends, where the cannulae are separately mounted in the hub off center of the central axis and where the proximal end of one cannula is penetrating the septum of the first reservoir and the other cannula is penetrating the septum of the second reservoir, such that both cannula are in fluid communication with medicament.
  • An injection device comprising the following in combination,
  • a needle assembly non-threadedly attached to the connector having a hub with a central axis containing at least two needle cannulae having distal and proximal ends, where the cannulae are separately mounted in the hub off center from the central axis and where the proximal ends of each cannulae are penetrating the septum and are in fluid communication with the medicament.
  • Figure 1 illustrates an arrangement of the needle assembly in accordance with the one aspect of the present disclosure
  • Figure 2 illustrates another arrangement of the needle assembly of the disclosure
  • Figure 3 illustrates yet another arrangement of the needle assembly of the disclosure
  • Figure 4 illustrates another arrangement of the needle assembly of the disclosure
  • Figure 5 illustrates the combination of the needle assembly with an injection device having two cartridges of medicament
  • Figure 6 illustrates another combination of the needle assembly with an injection device having one cartridge of medicament
  • Figure 7 illustrates another arrangement of the needle assembly of the disclosure.
  • FIG. 1 - 4 and 7 there is shown a needle assembly 1 having two cannulae 2 mounted in a hub 3. Although the Figures only show two cannulae, this disclosure includes two or more cannulas. Each hub 3 illustrated has a central axis defined by the dashed line 4. Each cannula has sharp or sharpened and beveled distal and/or proximal ends, designated by items 5 and 6, respectively. More specifically, the distal end of the needle assembly is designated by location 8 and the proximal end designated by location 9.
  • Figs. 1 , 2, 4 and 7 illustrate the configuration where the beveled portions of the distal ends of the needle cannulae are opposed and facing outwards. This configuration will help ensure that injected medicaments will not mix at the injection site.
  • the hub may have one or more non-threaded connectors 7 that allow it to be axially attached to injection device 20.
  • This connector can be any design known to the art, preferably one that is releasable by a user, for example, ramps and detents, snap locks, snap fits or other connector that has a male or female part that connects to the corresponding female or male part on the medicament housing 21 (Fig. 5).
  • the hub is permanently attached to the medicament housing and once the injection is completed the entire device is disposed.
  • Fig. 2 illustrates a specific embodiment where the needle cannula 10 is a different gauge than cannula 1 1 .
  • Figs. 3 and 4 illustrate situations were the proximal ends of the needle cannulae are spaced a distance D from each other and off center from the central axis 4, and the distal ends of the needle cannula are separated by >D and ⁇ D, respectively.
  • Fig. 3 also illustrates the situation where the beveled edges of the distal ends of the needle cannulae are facing inwards.
  • the beveled edges of the distal ends of the needle cannulae may face in any direction.
  • the beveled edges of the distal ends of the needle cannulae may face in the same direction, the beveled edges of the distal ends of the needle cannulae may face each other, or the beveled edges of the distal ends of the needle cannulae may face in opposite directions.
  • Fig. 4 illustrates one possible situation where the beveled edges of the distal ends of the needle cannulae face outwards, i.e., the beveled edges of the distal ends of the needle cannulae are facing outwards from the central axis 4 of the hub 3.
  • Figs. 5 and 6 show the needle assembly 1 attached to a drug delivery device having a medicament housing 21 , a dose dialing module 20, and dose adjustment knobs 22.
  • Fig. 5 illustrates an injection device having two medicament containers, e.g., two cartridges of medicament
  • Fig. 6 shows a device having a single medicament container, e.g., a single cartridge of medicament.
  • Fig. 7 shows a needle assembly that may be used with the device illustrated in Fig. 6 where D is much smaller than the distance between the distal ends of the needle cannula.
  • two or more needles are arranged within the needle attachment in such a manner as to permit all of the needles to pierce a single septum.
  • the needles are not connected and are arranged, possibly using curved or angled needles or needle cannulae 12 as illustrated in Figs. 3 and 7.
  • Part of the pain associated with an injection is caused by the insertion of the needle into the skin.
  • the insertion of needle gauges typically used in conjunction with injection devices, 27-31 G and smaller actually cause only a small amount of pain and/or sensation.
  • a further cause of injection pain is caused by the injected volume of medicament itself.
  • the injected medicament must create a space for itself in the sub-cutaneous tissue. This can be uncomfortable for users, particularly if the user is injecting larger volumes of medicament, say 0.4 ml and above.
  • One solution to this problem that is employed by users is to split the injection into two smaller injections and deliver them into different sites. This, however, requires the user to pierce the skin twice and repeat a number of the injection steps.
  • This disclosure where multiple needles are used in a single hub with a single reservoir of medicament may reduce the pain of the injection compared to a single needle, single injection, by splitting the injected volume into two or more smaller volume portions and delivering them to different sites simultaneously. This reduces the maximum volume of space that must be created in the tissue and also gives the medicament a larger surface area to volume ratio, which should promote dispersion of the fluid within the tissue during the injection. Thus, reducing the total volume of space that must be created in the tissue. Inserting a double needle clearly offers potential to be more painful than inserting a single needle, however, the preferred injection sites on the body do not have a high density of pain receptors.
  • the patient is unable to discern, at least from a pain perspective, whether the skin is being pierced by a single needle or by multiple needles. Inserting a double needle having beveled edges of the distal ends of the needle cannulae facing in opposite directions may help separating the two spaces in the tissue, where the medicament is administered.
  • Patient perception can also be a significant contributor to injection discomfort.
  • the visual appearance of multi needle hubs may be more intimidating to a user compared to a single needle.
  • the distal portion of the cannula i.e., the portion of the cannula extending beyond the distal end of the hub, is covered by a needle shield that prevents the user from seeing the needles (not shown).
  • the shield would be in the shielding or covering position both before and after the injection.
  • the needle shield would be retracted automatically by placing the needle shield against the patient's skin and pressing the injection device towards the body. After use, if the needle shield is locked in the needle covering position then the needle shield will also improve the safety of the multi needle hub by preventing accidental needle-stick injury.
  • the device of Fig. 5 is applicable where two or more medicaments are not suitable for co-formulation into one cartridge and where the mixing of the medicaments upon injection is undesirable for example due to chemical or physical instability, altered clinical or pharmacokinetic characteristics.
  • the needle assembly of this disclosure may be used for any multiple cartridge device, even where mixing is acceptable, because the double needle is less complicated to manufacture than previously known "Y-shaped" or "2 into 1 " needle designs and also offers potential for reduced injection force (by increasing the total needle cross-sectional area through which the fluid must pass) and reduced pain (by splitting the injection into two smaller portions and delivering them to different injection sites). This increased force to drive fluid through a "2 into 1 " needle is caused by a relatively tortuous fluid pathway which increases the resistance to fluid flow.
  • the distance between the distal ends of the cannulae may be 0.75 D or less or 0.5 D or less, preferably 0.3 D or less, particularly preferably 0.2 D or less, where D is the distance between the proximal ends of the cannulae. These distances facilitate piercing of a single skin fold.
  • the distance between the distal ends may be 1 .2 D or more, preferably 1 .3 D or more, particularly preferably 1 .5 D or more or 1 .75 D or more.
  • the needle assembly of Fig. 7 might also be used with any single cartridge injection device or applied to traditional injection syringes. The design is particularly applicable where the injected volume is high.
  • the distance between the proximal ends is much smaller than the distance between the distal ends.
  • the distance between the proximal ends is less than one-halve, e.g. 0.3 times or less, particularly preferably 0.2 times or less, the distance between the distal ends.
  • the drug delivery device of this disclosure may be a reusable or alternatively disposable.
  • disposable device it is meant an injection device that is obtained from the
  • the device may be a fixed dose or a settable dose, but in either case it is a multi-dose device.
  • immediate release preferably mean a pharmaceutical formulation containing at least one pharmaceutically active compound, wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a
  • the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever,
  • diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever,
  • ACS acute coronary syndrome
  • the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or
  • the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1 ) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
  • GLP-1 glucagon-like peptide
  • Insulin analogues are for example Gly(A21 ), Arg(B31 ), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin;
  • Des(B28-B30) human insulin Des(B27) human insulin and Des(B30) human insulin.
  • Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N- palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl- LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N- palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; ⁇ 29- ⁇ -( ⁇ - carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( -carboxy
  • Exendin-4 for example means Exendin-4(1 -39), a peptide of the sequence H-His-Gly- Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe- lle-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
  • Exendin-4 derivatives are for example selected from the following list of compounds:
  • H-(Lys)6-des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Lys6-des Pro36 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1 -39)-Lys6-NH2,
  • Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008,
  • Gonadotropine Follitropin, Lutropin, Choriongonadotropin
  • a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned
  • polysaccharides and/or a pharmaceutically acceptable salt thereof.
  • An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
  • Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
  • Acid addition salts are e.g. HCI or HBr salts.
  • Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion
  • R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
  • R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
  • solvates are for example hydrates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention porte sur un ensemble aiguille (1) pour un dispositif d'injection contenant au moins un réservoir de médicament, l'ensemble ayant un collet (3) comportant au moins deux canules d'aiguille séparées (2, 10, 11, 12), chacune ayant des extrémités distale et proximale pointues montées sur celle-ci et le collet ayant un connecteur non fileté (7) destiné à venir en prise avec le dispositif d'injection.
PCT/EP2011/062606 2010-07-26 2011-07-22 Ensemble aiguille multiple pour un dispositif d'injection WO2012013587A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36762610P 2010-07-26 2010-07-26
US61/367,626 2010-07-26
EP10181783 2010-09-29
EP10181783.1 2010-09-29

Publications (1)

Publication Number Publication Date
WO2012013587A1 true WO2012013587A1 (fr) 2012-02-02

Family

ID=43607937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/062606 WO2012013587A1 (fr) 2010-07-26 2011-07-22 Ensemble aiguille multiple pour un dispositif d'injection

Country Status (1)

Country Link
WO (1) WO2012013587A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3067079A1 (fr) * 2015-03-13 2016-09-14 Henke-Sass, Wolf GmbH Seringue dotée d'un premier et d'un second cylindre
EP2889051A4 (fr) * 2012-08-27 2016-11-02 Nanbu Plastics Co Ltd Aiguille d'injection
USRE47472E1 (en) 2012-03-14 2019-07-02 Becton, Dickinson And Company Passively activated safety needle assemblies and methods of use
US10589036B2 (en) 2016-12-13 2020-03-17 Becton, Dickinson And Company Safety needle device
US10661026B2 (en) 2016-12-13 2020-05-26 Becton, Dickinson And Company Safety needle device
US10792438B2 (en) 2016-12-13 2020-10-06 Becton, Dickinson And Company Safety needle devices
US10814073B2 (en) 2016-12-13 2020-10-27 Becton, Dickinson And Company Safety device with collapsible housing and trigger activation
US10918801B2 (en) 2016-12-13 2021-02-16 Becton, Dickinson And Company Caps for integrated fill and inject of safety needle devices
US11103651B2 (en) 2016-12-13 2021-08-31 Beckon, Dickinson and Company Safety needle devices
US11944792B2 (en) 2018-01-26 2024-04-02 Becton, Dickinson And Company Flush syringe with flip cap
US11975168B2 (en) 2019-11-18 2024-05-07 Becton, Dickinson And Company Disinfectant cap
US12029828B2 (en) 2020-03-05 2024-07-09 Becton, Dickinson And Company Disinfection cap

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2551902A (en) * 1948-09-10 1951-05-08 Arthur Schaffer Dehorning fluid ejector
US3572336A (en) * 1968-04-30 1971-03-23 Daniel R Hershberg Syringe
US4844089A (en) * 1986-05-14 1989-07-04 Lamberto Roberti Needle for multiple vacuum blood sample devices
DE3842317A1 (de) * 1988-12-16 1990-06-21 Medico S A Anordnung mit einer sterilen kanuele
US5360410A (en) * 1991-01-16 1994-11-01 Senetek Plc Safety syringe for mixing two-component medicaments
US20030050602A1 (en) * 2001-09-12 2003-03-13 Pettis Ronald J. Microneedle-based pen device for drug delivery and method for using same
US6641565B1 (en) * 1998-11-13 2003-11-04 Elan Pharma International Limited drug delivery systems and methods
WO2007035621A1 (fr) * 2005-09-16 2007-03-29 (Osi) Eyetech, Inc. Seringue oculaire
US20090099503A1 (en) * 2007-10-15 2009-04-16 Kunihiko Mitsuda Ozone treatment apparatus for acne
US20100056989A1 (en) * 2005-04-29 2010-03-04 Warsaw Orthopedic, Inc. Instrumentation for injection of therapeutic fluid into joints

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2551902A (en) * 1948-09-10 1951-05-08 Arthur Schaffer Dehorning fluid ejector
US3572336A (en) * 1968-04-30 1971-03-23 Daniel R Hershberg Syringe
US4844089A (en) * 1986-05-14 1989-07-04 Lamberto Roberti Needle for multiple vacuum blood sample devices
DE3842317A1 (de) * 1988-12-16 1990-06-21 Medico S A Anordnung mit einer sterilen kanuele
US5360410A (en) * 1991-01-16 1994-11-01 Senetek Plc Safety syringe for mixing two-component medicaments
US6641565B1 (en) * 1998-11-13 2003-11-04 Elan Pharma International Limited drug delivery systems and methods
US20030050602A1 (en) * 2001-09-12 2003-03-13 Pettis Ronald J. Microneedle-based pen device for drug delivery and method for using same
US20100056989A1 (en) * 2005-04-29 2010-03-04 Warsaw Orthopedic, Inc. Instrumentation for injection of therapeutic fluid into joints
WO2007035621A1 (fr) * 2005-09-16 2007-03-29 (Osi) Eyetech, Inc. Seringue oculaire
US20090099503A1 (en) * 2007-10-15 2009-04-16 Kunihiko Mitsuda Ozone treatment apparatus for acne

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MARK PUBLISHING COMPANY

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48049E1 (en) 2012-03-14 2020-06-16 Becton, Dickinson And Company Passively activated safety needle assemblies and methods of use
USRE47472E1 (en) 2012-03-14 2019-07-02 Becton, Dickinson And Company Passively activated safety needle assemblies and methods of use
EP2889051A4 (fr) * 2012-08-27 2016-11-02 Nanbu Plastics Co Ltd Aiguille d'injection
KR20160110172A (ko) 2015-03-13 2016-09-21 헨케-사스, 볼프 게엠베하 제1 및 제2 주사기 배럴을 갖는 주사기
US10238802B2 (en) 2015-03-13 2019-03-26 Henke-Sass, Wolf Gmbh Syringe with a first and a second syringe barrel
EP3067079A1 (fr) * 2015-03-13 2016-09-14 Henke-Sass, Wolf GmbH Seringue dotée d'un premier et d'un second cylindre
KR102501789B1 (ko) * 2015-03-13 2023-02-17 헨케-사스, 볼프 게엠베하 제1 및 제2 주사기 배럴을 갖는 주사기
US10589036B2 (en) 2016-12-13 2020-03-17 Becton, Dickinson And Company Safety needle device
US11559631B2 (en) 2016-12-13 2023-01-24 Becton, Dickinson And Company Safety needle device
US10792439B2 (en) 2016-12-13 2020-10-06 Becton, Dickinson And Company Safety needle devices
US10814073B2 (en) 2016-12-13 2020-10-27 Becton, Dickinson And Company Safety device with collapsible housing and trigger activation
US10918801B2 (en) 2016-12-13 2021-02-16 Becton, Dickinson And Company Caps for integrated fill and inject of safety needle devices
US11103651B2 (en) 2016-12-13 2021-08-31 Beckon, Dickinson and Company Safety needle devices
US11413402B2 (en) 2016-12-13 2022-08-16 Becton, Dickinson And Company Safety needle device
US10792438B2 (en) 2016-12-13 2020-10-06 Becton, Dickinson And Company Safety needle devices
US10661026B2 (en) 2016-12-13 2020-05-26 Becton, Dickinson And Company Safety needle device
US11642471B2 (en) 2016-12-13 2023-05-09 Becton, Dickinson And Company Safety device with collapsible housing and trigger activation
US12083327B2 (en) 2016-12-13 2024-09-10 Becton, Dickinson And Company Safety device with collapsible housing and trigger activation
US11944792B2 (en) 2018-01-26 2024-04-02 Becton, Dickinson And Company Flush syringe with flip cap
US11975168B2 (en) 2019-11-18 2024-05-07 Becton, Dickinson And Company Disinfectant cap
US12029828B2 (en) 2020-03-05 2024-07-09 Becton, Dickinson And Company Disinfection cap

Similar Documents

Publication Publication Date Title
WO2012013587A1 (fr) Ensemble aiguille multiple pour un dispositif d'injection
US9494264B2 (en) Coded drug reservoir connection element with hinge
US9227015B2 (en) Spring driven injection device with twin cartridges
US9844630B2 (en) Coded drug reservoir connection element with hinged flange
US9358349B2 (en) Guiding assembly for intradermal injection
US9089651B2 (en) Dose setting mechanism
US9849249B2 (en) Dose setting mechanism and method of setting a dose
US20130150802A1 (en) Coded cap for use with a drug delivery device
EP2555814A1 (fr) Élément de raccordement de réservoir de médicament codé pourvu d'éléments de blocage pliables
JP2013524906A (ja) 薬物送達デバイス用のコード化フェルール
JP2013533078A (ja) 薬物送達デバイスのための識別
US9649447B2 (en) Flexible fastener for drug delivery device
WO2012013585A1 (fr) Co-administration de deux médicaments dans une seule injection
WO2012010564A1 (fr) Cartouches de médicament ayant des dimensions non-standard
US8864722B2 (en) Cartridge holder and drug delivery device
EP2477680B1 (fr) Unité de verrouillage et de contrôle à intégrer dans un appareil médical
WO2012062718A1 (fr) Mécanisme d'établissement de dose destiné à un dispositif d'administration de médicament, système d'administration de médicaments et dispositif d'administration de médicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11734144

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11734144

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载